Goodwin advised Surface Oncology, Inc. (Surface) on the pricing of its initial public offering Surface Oncology, Inc. (“Surface”) (Nasdaq:SURF), a clinical-stage immuno-oncology company developing next-generation antibody…
Surface Oncology’s $119.5 Million Initial Public Offering
![](https://globallegalchronicle.com/wp-content/uploads/2018/02/abe9ed319e.jpeg)